- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07951047
Intraosseous Injection of Flurbiprofen Axetil for Postoperative Analgesia in Joint Arthroplasty
This single-center, prospective, randomized, double-blind, double-dummy controlled trial aims to evaluate the efficacy and safety of intraosseous versus intravenous flurbiprofen axetil for postoperative pain management in patients undergoing joint arthroplasty.
A total of 240 patients aged 65-80 years undergoing primary unilateral total knee arthroplasty, unicompartmental knee arthroplasty, total hip arthroplasty, or hemiarthroplasty will be enrolled. Participants will be stratified according to surgical procedure and randomly assigned in a 1:1 ratio to receive either intraosseous flurbiprofen axetil with intravenous saline placebo or intravenous flurbiprofen axetil with intraosseous saline placebo. The dose of flurbiprofen axetil will be 50 mg in both groups.
The primary outcome is postoperative pain intensity at rest, assessed using the Visual Analog Scale (VAS) at predefined time points from 1 hour to 6 weeks after surgery. Secondary outcomes include pain during movement, cumulative opioid consumption within 72 hours, length of hospital stay, joint functional recovery, patient satisfaction, patient-controlled analgesia utilization, and adverse events.
This study aims to determine whether intraosseous administration of flurbiprofen axetil provides effective and safe postoperative analgesia compared with conventional intravenous administration following joint arthroplasty.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Hua Luo, Dr.
- Número de teléfono: 0576-85190463
- Correo electrónico: luohua66ry@163.com
Ubicaciones de estudio
-
-
Zhejiang
-
Linhai, Zhejiang, Porcelana, 317000
- Reclutamiento
- No. 150 Ximen Road
-
Contacto:
- Hua Luo
- Número de teléfono: 0576-85190463
- Correo electrónico: luohua66ry@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults aged 65 to 80 years, regardless of sex.
- Patients scheduled to undergo unilateral joint arthroplasty.
- Patients scheduled for elective surgery with standardized surgical procedures and prosthesis types, consistent with the postoperative analgesia protocol of this study.
- Patients scheduled to receive general anesthesia.
- Patients who are able to understand the study objectives, procedures, and potential risks, voluntarily provide written informed consent, and cooperate with postoperative assessments, including Visual Analog Scale (VAS) pain scores, functional assessments, and patient satisfaction evaluations.
Exclusion Criteria:
- Known hypersensitivity to flurbiprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs), or contraindications to opioids or other medications used in the study.
- Contraindications to NSAID use, including peptic ulcer disease, gastrointestinal bleeding, severe hepatic or renal impairment, or coagulation disorders.
- Severe cardiovascular, hepatic, renal, hematological, or central nervous system diseases that may prevent patients from tolerating general anesthesia or analgesic medications.
- Recent history of gastrointestinal bleeding or active peptic ulcer disease.
- Severe infection, immunodeficiency, or risk of sepsis.
- Psychiatric disorders or cognitive impairment that prevent reliable assessment of postoperative pain intensity or patient satisfaction.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intraosseous Flurbiprofen
Participants will receive a total dose of 50 mg flurbiprofen axetil via intraosseous administration. For knee arthroplasty, the medication will be administered into the distal femoral and proximal tibial bone cavities. For hip arthroplasty, the medication will be administered into the bone cavity near the greater trochanter. |
Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty. Flurbiprofen axetil 50 mg will be administered intravenously. |
|
Comparador activo: Intravenous Flurbiprofen Axetil
Participants will receive 50 mg flurbiprofen axetil through intravenous administration. |
Flurbiprofen axetil 50 mg will be administered intraosseously into the distal femoral and proximal tibial bone cavities for knee arthroplasty or near the greater trochanter for hip arthroplasty. Flurbiprofen axetil 50 mg will be administered intravenously. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Visual Analog Scale
Periodo de tiempo: At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.
|
Postoperative pain intensity at rest will be assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. |
At 1, 2, 3, 4, 5, 6, 12, 24, 48, and 72 hours after surgery; postoperative day 7; and postoperative weeks 2 and 6.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cumulative Opioid Consumption Within 72 Hours
Periodo de tiempo: up to 72 hours post-surgery
|
The cumulative dose of opioid analgesics administered during the first 72 hours after surgery will be recorded. Opioid consumption will be converted into morphine milligram equivalents to facilitate comparison between the two treatment groups. |
up to 72 hours post-surgery
|
|
Length of Hospital Stay
Periodo de tiempo: From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
|
The length of hospital stay will be calculated as the number of days from hospital admission to hospital discharge. The duration of hospitalization will be compared between the two treatment groups. Unit: days. |
From the date of hospital admission to the date of hospital discharge, assessed up to 30 days.
|
|
Knee Society Score
Periodo de tiempo: At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
|
Postoperative knee function will be evaluated using the Knee Society Score (KSS). Scores are recorded at predefined postoperative time points and compared between the two treatment groups to assess functional recovery. Unit: score. |
At baseline (preoperative assessment), postoperative days 1, 3, and 7, and postoperative weeks 2 and 6.
|
|
Patient Satisfaction With Postoperative Analgesia
Periodo de tiempo: At hospital discharge.
|
Patient satisfaction with postoperative analgesia will be assessed using a 10-point Numerical Rating Scale (NRS), ranging from 0 (completely dissatisfied) to 10 (completely satisfied). Higher scores indicate greater satisfaction. Unit: score. |
At hospital discharge.
|
|
Cumulative PCA Analgesic Consumption
Periodo de tiempo: From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
|
The cumulative amount of analgesic medication delivered through the patient-controlled analgesia (PCA) system will be recorded from PCA initiation until discontinuation. The total medication consumption will be expressed in milligrams (mg), and the duration of PCA use will also be recorded. Unit: mg. |
From PCA initiation to PCA discontinuation, within the first 72 hours after surgery.
|
|
Incidence of Adverse Events
Periodo de tiempo: up to 3 months post-surgery
|
The incidence of adverse events will be assessed in both treatment groups. Recorded events will include gastrointestinal bleeding, renal impairment, cardiovascular events, and wound infection ect. |
up to 3 months post-surgery
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Lawal OD, Gold J, Murthy A, Ruchi R, Bavry E, Hume AL, Lewkowitz AK, Brothers T, Wen X. Rate and Risk Factors Associated With Prolonged Opioid Use After Surgery: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Jun 1;3(6):e207367. doi: 10.1001/jamanetworkopen.2020.7367.
- Hah JM, Bateman BT, Ratliff J, Curtin C, Sun E. Chronic Opioid Use After Surgery: Implications for Perioperative Management in the Face of the Opioid Epidemic. Anesth Analg. 2017 Nov;125(5):1733-1740. doi: 10.1213/ANE.0000000000002458.
- McNamara CA, Laurita J, Lambert BS, Sullivan TC, Clyburn TA, Incavo SJ, Park KJ. A multimodal intraosseous infusion of morphine and ketorolac decreases early postoperative pain and opioid consumption following total knee arthroplasty. Knee. 2023 Aug;43:129-135. doi: 10.1016/j.knee.2023.06.002. Epub 2023 Jul 1.
- Zhao C, Liao Q, Yang D, Yang M, Xu P. Advances in perioperative pain management for total knee arthroplasty: a review of multimodal analgesic approaches. J Orthop Surg Res. 2024 Dec 19;19(1):843. doi: 10.1186/s13018-024-05324-4.
- Hafeez K, Umar M, Desai V. Factors delaying mobilization after hip and knee arthroplasty. Int J Health Sci (Qassim). 2024 Sep-Oct;18(5):4-7.
- Haffar A, Fillingham YA, Breckenridge L, Gursay D, Lonner JH. Meloxicam versus Celecoxib for Postoperative Analgesia after Total Knee Arthroplasty: Safety, Efficacy and Cost. J Am Acad Orthop Surg Glob Res Rev. 2022 Apr 5;6(4):e22.00032. doi: 10.5435/JAAOSGlobal-D-22-00032.
- Ng JS, van der Werf B, Nicholson L, Farrington W, Young SW. The AAHKS Clinical Research Award: Intraosseous Regional Diclofenac for Postoperative Pain Management in Total Knee Arthroplasty. J Arthroplasty. 2025 Sep;40(S19):S18-S27. doi: 10.1016/j.arth.2025.05.013. Epub 2025 May 9.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- K20251066
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .